局部晚期宫颈癌根治性放化疗前诱导化疗的多中心队列研究
该多中心队列研究重新评估了诱导化疗(IC)在局部晚期宫颈癌(LACC)患者中的意义,并探索哪些患者可能最大获益。通过RPA风险分层发现,低危亚组(I/II期且鳞癌)接受IC者5年OS和PFS更差,而中危和高危亚组无显著生存差异;ICPD>0.05者生存更优,尤其在高危亚组中ICPD>0.05者5年OS优于未接受IC者。结论提示IC不应常规推荐给所有LACC患者,高危患者以ICPD>0.05接受IC可能额外获益。
要点
- 低危LACC患者接受IC的5年OS和PFS显著更差,不应常规推荐。
- 中危和高危亚组中IC与无IC的生存差异无统计学意义。
- ICPD>0.05者生存更优,高危亚组中ICPD>0.05者5年OS优于无IC者。
核心结论
- IC可能损害低危LACC患者的生存,不应常规推荐给所有接受根治性放疗的LACC患者。
- 高危LACC患者以ICPD>0.05接受IC可获得额外生存获益。
研究设计与样本
- 多中心队列研究,采用Kaplan-Meier法和Log-rank检验比较累积生存率,Cox回归分析识别危险因素。
- 通过递归分割分析(RPA)建立风险分层系统,并以限制性立方样条(RCS)分析确定ICPD最佳截断值。
主要发现
- RPA识别出三个风险亚组:低危(I/II期且鳞癌)、中危(I/II期且腺癌或腺鳞癌)、高危(III/IVA期)。
- 低危亚组中,IC组5年OS为79.7% vs 89.6%(P=0.013),5年PFS为69.3% vs 81.4%(P=0.05),均差于无IC组。
- 中危和高危亚组中,IC与无IC的生存差异均无统计学意义(All P>0.05)。
- ICPD>0.05者5年OS为80.6% vs 66.7%(P<0.001),5年PFS为73.2% vs 64.1%(P=0.048),均优于ICPD≤0.05者。
- 高危亚组中,ICPD>0.05者5年OS为90.0% vs 71.1%(P<0.001),优于无IC者。
关键数值与推荐
- 低危亚组:I/II期且鳞癌;中危亚组:I/II期且腺癌或腺鳞癌;高危亚组:III/IVA期。
- ICPD定义为IC周期数除以从IC开始至放疗开始的时间间隔,最佳截断值为0.05。
临床怎么用
- 对低危LACC患者(I/II期且鳞癌)不常规推荐IC。
- 高危LACC患者可考虑IC,但需控制ICPD>0.05以争取生存获益。
- 中危患者IC与否需个体化决策,因生存差异无统计学意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To reappraise the significance of induction chemotherapy (IC) for locally advanced cervical cancer (LACC) patients and to determine which patients might benefit most from IC. METHODS: The cumulative survival rates were estimated and compared via Kaplan-Meier method and Log-rank test, respectively. Cox regression analysis was performed to identify risk factors. A risk stratification system was derived from the recursive partitioning analysis (RPA). The induction course per day (ICPD) was defined as the number of IC cycles divided by the interval from IC initiation to radiotherapy start. The optimal cut-off value of ICPD was determined by restricted cubic spline (RCS) analysis. RESULTS: Three risk subgroups were identified through RPA. Patients with IC had worse 5-yr overall survival (OS) (79.7% VS 89.6%; P = 0.013) and 5-yr progression free survival (PFS) (69.3% VS 81.4%; P = 0.05) than those without IC in low-risk subgroup (stage I/II and squamous cell carcinoma). No significant survival differences were observed between patients receiving IC and those without in middle-risk (stage I/II and adenocarcinoma or adenosquamous) or high-risk subgroup (stage III/IVA) (All P > 0.05). Patients with ICPD > 0.05 had significantly better 5-year OS (80.6% vs. 66.7%; P < 0.001) and 5-year PFS (73.2% vs. 64.1%; P = 0.048) relative to those with ICPD ≤ 0.05. In high-risk subgroup, patients with ICPD > 0.05 achieved superior 5-year OS compared with those without IC (90.0% vs. 71.1%; P < 0.001). CONCLUSIONS: IC might compromise the survival for low-risk LACC patients and should not be routinely recommended for every LACC patients undergoing definitive radiotherapy. High-risk LACC patients treated with IC at ICPD > 0.05 achieved additional survival benefits.
引用
- Yang XL, Li XM, Shi YG, et al. Induction chemotherapy prior to definitive chemoradiotherapy in locally advanced cervical cancer patients: A multi-center cohort study. Radiother Oncol. 2026. PMID: 42362088. doi:10.1016/j.radonc.2026.111675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。